会議の疲労を克服する.

Same author

Evaluating the adaptation rates for esophageal cancer: Impact of the setup error contribution and of the dosimetric threshold.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2026

Same author

Scalable, memory-efficient robust proton therapy optimization through beamlet-free treatment planning.

Medical physics·2025

Same author

Dynamic proton arc treatment planning study for oesophageal cancer.

Physics and imaging in radiation oncology·2025

Same author

Towards faster plan adaptation for proton arc therapy using initial treatment plan information.

Physics and imaging in radiation oncology·2025

Same author

Anticipating potential bottlenecks in adaptive proton FLASH therapy: a ridge filter reuse strategy.

Physics in medicine and biology·2025

Same author

Proton arc therapy plan optimization with energy layer pre-selection driven by organ at risk sparing and delivery time.

Physics in medicine and biology·2025

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

会議の疲労を克服する.

関連する概念動画

Evaluating the adaptation rates for esophageal cancer: Impact of the setup error contribution and of the dosimetric threshold.

Scalable, memory-efficient robust proton therapy optimization through beamlet-free treatment planning.

Dynamic proton arc treatment planning study for oesophageal cancer.

Towards faster plan adaptation for proton arc therapy using initial treatment plan information.

Anticipating potential bottlenecks in adaptive proton FLASH therapy: a ridge filter reuse strategy.

Proton arc therapy plan optimization with energy layer pre-selection driven by organ at risk sparing and delivery time.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

会議の疲労を克服する.

関連する概念動画

関連記事

Evaluating the adaptation rates for esophageal cancer: Impact of the setup error contribution and of the dosimetric threshold.

Scalable, memory-efficient robust proton therapy optimization through beamlet-free treatment planning.

Dynamic proton arc treatment planning study for oesophageal cancer.

Towards faster plan adaptation for proton arc therapy using initial treatment plan information.

Anticipating potential bottlenecks in adaptive proton FLASH therapy: a ridge filter reuse strategy.

Proton arc therapy plan optimization with energy layer pre-selection driven by organ at risk sparing and delivery time.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.